Mineral and Bone Disorders in Kidney Transplant Recipients: Reversible, Irreversible, and De Novo Abnormalities

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 May 2

PMID 25931403

Citations 10

Authors

Takashi Hirukawa

Takatoshi Kakuta

Michio Nakamura

Masafumi Fukagawa

Affiliations

Soon will be listed here.

Abstract

Given the advances in medical technologies related to kidney transplantation, the post-transplant graft survival rate and quality of life have improved dramatically. Nevertheless, post-transplant mortality rate still remains high as compared to the general population due to the development of cardiovascular events. It has recently been widely recognized that chronic kidney disease-mineral and bone disorders (CKD-MBD) significantly contribute to such poor prognosis at least in part. In the majority of kidney recipients, abnormal serum parameters for mineral and bone disorder (MBD), such as phosphorus, calcium, 1,25-dihydroxyvitamin D, parathyroid hormone and fibroblast growth factor 23, gradually return toward acceptable levels following the re-establishment of kidney function after transplantation; however, some irreversible abnormalities, developed as the result of long-term dialysis, persist, require treatment, or even progress after kidney transplantation. Thus, better management of CKD-MBD during pre-dialysis and dialysis period as well as after kidney transplantation is highly appreciated.

Citing Articles

Prevalence of Musculoskeletal and Metabolic Disorders in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.

Herreros-Carretero A, Berlanga-Macias C, Martinez-Vizcaino V, Torres-Costoso A, Pascual-Morena C, Hernandez-Castillejo L Transpl Int. 2024; 37():12312.

PMID: 38720821 PMC: 11076774. DOI: 10.3389/ti.2024.12312.

Outcome of surgical parathyroidectomy for tertiary hyperparathyroidism in kidney transplant recipients: tertiary hyperparathyroidism should not be ignored, for the sake of precious allografts.

Nakamura M, Takiguchi S, Uehara S, Tomita Y Ren Fail. 2024; 46(1):2333919.

PMID: 38575330 PMC: 10997355. DOI: 10.1080/0886022X.2024.2333919.

Mineral and bone disorder after kidney transplantation: a single-center cohort study.

Sun L, Wang Z, Zheng M, Hang Z, Liu J, Gao X Ren Fail. 2023; 45(1):2210231.

PMID: 37183797 PMC: 10187110. DOI: 10.1080/0886022X.2023.2210231.

Bone volume, mineral density, and fracture risk after kidney transplantation.

Keronen S, Martola L, Finne P, Burton I, Tong X, Kroger H PLoS One. 2022; 17(3):e0261686.

PMID: 35349587 PMC: 8963906. DOI: 10.1371/journal.pone.0261686.

Clinical Prediction of High-Turnover Bone Disease After Kidney Transplantation.

Keronen S, Martola L, Finne P, Burton I, Tong X, Kroger H Calcif Tissue Int. 2021; 110(3):324-333.

PMID: 34668028 PMC: 8860959. DOI: 10.1007/s00223-021-00917-1.

References

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama J . Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013; 17(3):247-88. DOI: 10.1111/1744-9987.12058. View

Stehman-Breen C, Sherrard D, Alem A, Gillen D, Heckbert S, Wong C . Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58(5):2200-5. DOI: 10.1111/j.1523-1755.2000.00394.x. View

Taniguchi M, Tokumoto M, Matsuo D, Motoyama K, Sugitani A, Kuroki S . Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006; 70(2):363-70. DOI: 10.1038/sj.ki.5001549. View

Kruse A, Eisenberger U, Frey F, Mohaupt M . The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005; 20(7):1311-4. DOI: 10.1093/ndt/gfh924. View

Yeo H, Beck L, McDonald J, Zayzafoon M . Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone. 2007; 40(6):1502-16. PMC: 1974856. DOI: 10.1016/j.bone.2007.02.017. View

Malyszko J, Wolczynski S, Malyszko J, Konstantynowicz J, Kaczmarski M, Mysliwiec M . Correlations of new markers of bone formation and resorption in kidney transplant recipients. Transplant Proc. 2003; 35(4):1351-4. DOI: 10.1016/s0041-1345(03)00523-2. View

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

Carpenter T, Imel E, Ruppe M, Weber T, Klausner M, Wooddell M . Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014; 124(4):1587-97. PMC: 3973088. DOI: 10.1172/JCI72829. View

Bergua C, Torregrosa J, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol J . Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation. 2008; 86(3):413-7. DOI: 10.1097/TP.0b013e31817c13e1. View

10.

DeLoach S, Joffe M, Mai X, Goral S, Rosas S . Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant. 2009; 24(4):1314-9. PMC: 2721431. DOI: 10.1093/ndt/gfn753. View

11.

Lehmann G, Ott U, Stein G, Steiner T, Wolf G . Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007; 39(10):3153-8. DOI: 10.1016/j.transproceed.2007.10.001. View

12.

Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Ando K, Nakajima I . Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial. 2011; 15(5):481-7. DOI: 10.1111/j.1744-9987.2011.00932.x. View

13.

Kunzendorf U, Kramer B, Arns W, Braun J, Grossmann J, Pietruck F . Bone disease after renal transplantation. Nephrol Dial Transplant. 2007; 23(2):450-8. DOI: 10.1093/ndt/gfm816. View

14.

Bagni B, Gilli P, Cavallini A, Bagni I, Marzola M, Orzincolo C . Continuing loss of vertebral mineral density in renal transplant recipients. Eur J Nucl Med. 1994; 21(2):108-12. DOI: 10.1007/BF00175756. View

15.

Shroff R, Long D, Shanahan C . Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2012; 24(2):179-89. DOI: 10.1681/ASN.2011121191. View

16.

Cundy T, Kanis J, Heynen G, Morris P, Oliver D . Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med. 1983; 52(205):67-78. View

17.

Kruse A, Eisenberger U, Frey F, Mohaupt M . Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2007; 22(8):2362-5. DOI: 10.1093/ndt/gfm270. View

18.

Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B . FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014; 6(6):744-59. PMC: 4203353. DOI: 10.1002/emmm.201303716. View

19.

Zhang R, Chouhan K . Metabolic bone diseases in kidney transplant recipients. World J Nephrol. 2013; 1(5):127-33. PMC: 3782213. DOI: 10.5527/wjn.v1.i5.127. View

20.

Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T . The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13):1207-15. DOI: 10.1056/NEJMoa031975. View